Literature DB >> 15361123

Development of a multiplex PCR-SSP method for Killer-cell immunoglobulin-like receptor genotyping.

J Y Sun1, L Gaidulis, M M Miller, R M Goto, R Rodriguez, S J Forman, D Senitzer.   

Abstract

Killer-cell immunoglobulin-like receptors (KIRs) on natural killer (NK) cells recognize groups of HLA class I alleles. Recent work suggests that KIR genotype may affect the outcome of hematopoietic stem-cell transplants and that prospective KIR typing maybe of benefit in future matching of donors and recipients. A simple and informative KIR genotyping method was developed using a multiplex polymerase chain reaction-sequence-specific primer strategy. This method contains four multiplex reactions for detecting all functional KIR genes, including some 2DS4 variants that harbor a common deletion. Primer pairs were designed to provide short amplicons (108-565 bp) that can be analyzed by agarose gel electrophoreses or by automated electrophoretic systems. This method was evaluated in a blinded survey with the NK/KIR Phase II QC Panel (a total of 16 cell lines) from the 14th International Histocompatibility Workshop (IHWS), and the results are 100% concordant with the consensus genotype. Results in further KIR genotyping of 20 reference cell lines from the 10th IHWS were consistent with previously published genotypes, matching those of one study in instances where different genotypes have been previously reported. The genotypes obtained in this study may be helpful to other labs developing KIR genotyping methods in resolving typing discrepancies and in detecting common deletion variants of 2DS4. This method can save labor and reagent costs. It provides good results from partially degraded template DNA due to short amplicons in this method. It is convenient to use in both clinical and research laboratories.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15361123     DOI: 10.1111/j.1399-0039.2004.00303.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  18 in total

1.  Use of killer cell immunoglobulin-like receptor genes as early markers of hematopoietic chimerism after double-umbilical cord blood transplantation.

Authors:  Pauline Rettman; Nolwenn Legrand; Catherine Willem; Laurence Lodé; Patrice Chevallier; Anne Cesbron; David Senitzer; Christelle Retière; Katia Gagne
Journal:  Haematologica       Date:  2015-07-23       Impact factor: 9.941

2.  An improved RT-PCR method for the detection of killer-cell immunoglobulin-like receptor (KIR) transcripts.

Authors:  A Thompson; A R van der Slik; F Koning; J van Bergen
Journal:  Immunogenetics       Date:  2006-10-11       Impact factor: 2.846

3.  Severe Symptomatic Primary Human Cytomegalovirus Infection despite Effective Innate and Adaptive Immune Responses.

Authors:  Raphaëlle Riou; Céline Bressollette-Bodin; David Boutoille; Katia Gagne; Audrey Rodallec; Maeva Lefebvre; François Raffi; David Senitzer; Berthe-Marie Imbert-Marcille; Christelle Retière
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

4.  Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infection.

Authors:  Ghislaine M Gallez-Hawkins; Anne E Franck; Xiuli Li; Lia Thao; Arisa Oki; Ketevan Gendzekhadze; Andrew Dagis; Joycelynne Palmer; Ryotaro Nakamura; Stephen J Forman; David Senitzer; John A Zaia
Journal:  Biol Blood Marrow Transplant       Date:  2011-04-29       Impact factor: 5.742

5.  Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates.

Authors:  Ryotaro Nakamura; Nademanee Auayporn; David D Smith; Joycelynne Palmer; Joel Y Sun; Jeffrey Schriber; Vinod Pullarkat; Pablo Parker; Roberto Rodriguez; Anthony Stein; Joseph Rosenthal; Shirong Wang; Chatchada Karanas; Karl Gaal; David Senitzer; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2008-04       Impact factor: 5.742

6.  Frequencies of killer immunoglobulin-like receptor genotypes influence susceptibility to spontaneous abortion.

Authors:  I Nowak; A Malinowski; H Tchorzewski; E Barcz; J R Wilczynski; M Grybos; M Kurpisz; W Luszczek; M Banasik; D Reszczynska-Slezak; E Majorczyk; A Wisniewski; D Senitzer; J Yao Sun; P Kusnierczyk
Journal:  J Appl Genet       Date:  2009       Impact factor: 3.240

7.  The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation.

Authors:  John A Zaia; Joel Y Sun; Ghislaine M Gallez-Hawkins; Lia Thao; Arisa Oki; Simon F Lacey; Andrew Dagis; Joycelynne Palmer; Don J Diamond; Stephen J Forman; David Senitzer
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

8.  Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.

Authors:  Ryotaro Nakamura; Ketevan Gendzekhadze; Joycelynne Palmer; Ni-Chun Tsai; Sally Mokhtari; Stephen J Forman; John A Zaia; David Senitzer; Guido Marcucci; Anthony Stein
Journal:  Leuk Res       Date:  2019-09-28       Impact factor: 3.156

9.  Killer immunoglobulin-like receptor (KIR) and HLA genotypes affect the outcome of allogeneic kidney transplantation.

Authors:  Izabela Nowak; Maria Magott-Procelewska; Agnieszka Kowal; Maciej Miazga; Marta Wagner; Wanda Niepiekło-Miniewska; Małgorzata Kamińska; Andrzej Wiśniewski; Edyta Majorczyk; Marian Klinger; Wioleta Łuszczek; Andrzej Pawlik; Rafał Płoski; Ewa Barcz; David Senitzer; Piotr Kuśnierczyk
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

10.  Donor killer immunoglobulin-like receptor genes and reactivation of cytomegalovirus after HLA-matched hematopoietic stem-cell transplantation: HLA-C allotype is an essential cofactor.

Authors:  Carolyn E Behrendt; Ryotaro Nakamura; Stephen J Forman; John A Zaia
Journal:  Front Immunol       Date:  2013-02-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.